PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma

PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma

Adrenocortical carcinoma (ACC) is an aggressive malignancy with limited treatment options. Polo-like kinase 1 (PLK1) is a promising drug target; PLK1 inhibitors (PLK1i) have been investigated in solid cancers and are more effective in TP53-mutated cases. We evaluated PLK1 expression in ACC samples a...

Full description

Bibliographic Details
Main Authors: Emily Warmington, Gabrielle Smith, Vasileios Chortis, Raimunde Liang, Juliane Lippert, Sonja Steinhauer, Laura-Sophie Landwehr, Constanze Hantel, Katja Kiseljak-Vassiliades, Margaret E Wierman, Barbara Altieri, Paul A Foster, Cristina L Ronchi
Format: Article
Language:English
Published: Bioscientifica 2023-12-01
Series:Endocrine Connections
Subjects:
adrenocortical carcinoma
polo-like kinase 1
molecular-targeted therapy
Online Access:https://ec.bioscientifica.com/view/journals/ec/13/1/EC-23-0403.xml

Internet

https://ec.bioscientifica.com/view/journals/ec/13/1/EC-23-0403.xml

Similar Items